This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carr, M. C. Articles by Brunzell, J. D. Search for Related Content PubMed PubMed Citation Articles by Carr, M. C. Articles by Brunzell, J. D.

Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk

Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, Washington 98195-6426

Address all correspondence and requests for reprints to: Molly C. Carr, M.D., Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Box 356426, Seattle, Washington 98195-6426. E-mail: carr{at}u.washington.edu.

Regional body fat distribution has an important influence on metabolic and cardiovascular risk factors. Increased abdominal (visceral) fat accumulation is a risk factor for coronary artery disease (CAD), dyslipidemia, hypertension, stroke, and type 2 diabetes. The recent emphasis on treatment of the dyslipidemia of the metabolic syndrome (hypertriglyceridemia, reduced high-density lipoprotein, and increased small, dense low-density lipoprotein particle number) has compelled practitioners to consider lipid-lowering therapy in a greater number of their patients, as one in two individuals over age 50 has the metabolic syndrome. Individuals with the metabolic syndrome typically have normal low-density lipoprotein cholesterol levels, and current lipid-lowering guidelines may underestimate their cardiovascular risk. Two subgroups of patients with the metabolic syndrome are at particularly high risk for premature CAD. One, individuals with type 2 diabetes, accounts for 20–30% of early cardiovascular disease. The second, familial combined hyperlipidemia, accounts for an additional 10–20% of premature CAD. Familial combined hyperlipidemia is characterized by the metabolic syndrome in addition to a disproportionate elevation of apolipoprotein B levels. The measurement of fasting glucose and apolipoprotein B, in addition to the fasting lipid profile, can help to estimate CAD risk in patients with the metabolic syndrome.

This work was supported by NIH Grants HL-64322, HL-30086, and DK-02456 and K23 Award RR-16067 (to M.C.C.) and by University of Washington General Clinical Research Center (M01-RR-00037).

Abbreviations: apo, Apolipoprotein; CAD, coronary artery disease; DM2, type 2 diabetes; FCHL, familial combined hyperlipidemia; FFA, free fatty acid; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; NCEP, National Cholesterol Education Program; NHANES III, National Health and Nutrition Examination Survey III; VLDL, very LDL.

This article has been cited by other articles:

				K. Guo, J. Mogen, S. Struzzi, and Y. Zhang Preadipocyte transplantation: an in vivo study of direct leptin signaling on adipocyte morphogenesis and cell size Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1339 - R1347. [Abstract] [Full Text] [PDF]

				M. Bosevski, V. Borozanov, S. Tosev, I. Peovska, S. Meskovska-Bongard, and L. Georgievska-Ismail Predictors for Peripheral and Carotid Revascularization in a Population-Based Cohort With Type 2 Diabetes Angiology, February 1, 2009; 60(1): 46 - 49. [Abstract] [PDF]

				F. Civeira, E. Jarauta, A. Cenarro, A. L. Garcia-Otin, D. Tejedor, D. Zambon, M. Mallen, E. Ros, and M. Pocovi Frequency of Low-Density Lipoprotein Receptor Gene Mutations in Patients With a Clinical Diagnosis of Familial Combined Hyperlipidemia in a Clinical Setting J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1546 - 1553. [Abstract] [Full Text] [PDF]

				G. K. Andrikopoulos and S. Tzeis Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism Angiology, August 1, 2008; 59(2_suppl): 44S - 48S. [Abstract] [PDF]

				Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]

				J. D. Brunzell Hypertriglyceridemia N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017. [Full Text] [PDF]

				H. J. Schneider, H. Glaesmer, J. Klotsche, S. Bohler, H. Lehnert, A. M. Zeiher, W. Marz, D. Pittrow, G. K. Stalla, H.-U. Wittchen, et al. Accuracy of Anthropometric Indicators of Obesity to Predict Cardiovascular Risk J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 589 - 594. [Abstract] [Full Text] [PDF]

				C. Pitombo, E. P Araujo, C. T De Souza, J. C Pareja, B. Geloneze, and L. A Velloso Amelioration of diet-induced diabetes mellitus by removal of visceral fat J. Endocrinol., December 1, 2006; 191(3): 699 - 706. [Abstract] [Full Text] [PDF]

				R. T. de Jongh, R. G. Ijzerman, E. H. Serne, J. J. Voordouw, J. S. Yudkin, H. A. D.-v. de Waal, C. D. A. Stehouwer, and M. M. van Weissenbruch Visceral and Truncal Subcutaneous Adipose Tissue Are Associated with Impaired Capillary Recruitment in Healthy Individuals J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5100 - 5106. [Abstract] [Full Text] [PDF]

				Y. Asato, K. Katsuren, T. Ohshiro, K. Kikawa, T. Shimabukuro, and T. Ohta Relationship Between Lipid Abnormalities and Insulin Resistance in Japanese School Children Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2781 - 2786. [Abstract] [Full Text] [PDF]

				M. Marcil, H. Vu, W. Cui, Z. Dastani, J. C. Engert, D. Gaudet, M. Castro-Cabezas, A. D. Sniderman, J. Genest Jr, and K. Cianflone Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1619 - 1625. [Abstract] [Full Text] [PDF]

				G. Bronner, A. M. Sattler, A. Hinney, M. Soufi, F. Geller, H. Schafer, B. Maisch, J. Hebebrand, and J. R. Schaefer The 103I Variant of the Melanocortin 4 Receptor Is Associated with Low Serum Triglyceride Levels J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 535 - 538. [Abstract] [Full Text] [PDF]

				S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, October 25, 2005; 112(17): 2735 - 2752. [Full Text] [PDF]

				O. Sandu, K. Song, W. Cai, F. Zheng, J. Uribarri, and H. Vlassara Insulin Resistance and Type 2 Diabetes in High-Fat-Fed Mice Are Linked to High Glycotoxin Intake Diabetes, August 1, 2005; 54(8): 2314 - 2319. [Abstract] [Full Text] [PDF]

				E. A. Nordstrom, M. Ryden, E. C. Backlund, I. Dahlman, M. Kaaman, L. Blomqvist, B. Cannon, J. Nedergaard, and P. Arner A Human-Specific Role of Cell Death-Inducing DFFA (DNA Fragmentation Factor-{alpha})-Like Effector A (CIDEA) in Adipocyte Lipolysis and Obesity Diabetes, June 1, 2005; 54(6): 1726 - 1734. [Abstract] [Full Text] [PDF]

				L.-A. Li and P.-W. Wang PCB126 Induces Differential Changes in Androgen, Cortisol, and Aldosterone Biosynthesis in Human Adrenocortical H295R Cells Toxicol. Sci., May 1, 2005; 85(1): 530 - 540. [Abstract] [Full Text] [PDF]

				J. D. Brunzell Increased ApoB in Small Dense LDL Particles Predicts Premature Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 474 - 475. [Full Text] [PDF]

				P. Barter The realities of dyslipidaemia in metabolic syndrome and diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1_suppl): S7 - S11. [Abstract] [PDF]

				G. F. Lewis, S. Murdoch, K. Uffelman, M. Naples, L. Szeto, A. Albers, K. Adeli, and J. D. Brunzell Hepatic Lipase mRNA, Protein, and Plasma Enzyme Activity Is Increased in the Insulin-Resistant, Fructose-Fed Syrian Golden Hamster and Is Partially Normalized by the Insulin Sensitizer Rosiglitazone Diabetes, November 1, 2004; 53(11): 2893 - 2900. [Abstract] [Full Text] [PDF]